March 14, 2025

CADM Misdiagnosed Twice as Often as DM, Linked to Poorer Outcomes

Study reveals CADM patients face twice the misdiagnosis rate of DM patients, with diagnostic delays associated with increased hospitalization and ILD risks.

Conexiant

March 13, 2025

FDA Chief Counsel Resigns Two Days In

U.S. FDA's chief counsel resigns amidst controversy surrounding her appointment and connections to mifepristone during the Biden administration.

Reuters

March 11, 2025

Doctors Never Truly Vacation, Study Reveals

"Organizations should implement strategies to minimize clinical tasks during PTO."

Conexiant

March 07, 2025

Novel Therapies Advance Psychiatric Treatment Options

New research has found intranasally administered esketamine's effects are short-lived. tDCS shows promise for depression, ondansetron has limited OCD impact, and Cobenfy enhances cognition in schizophrenia.

Conexiant

March 06, 2025

COVID-19 Increases Autoimmune Blistering Disease Risk, Study Finds

COVID-19 infection significantly increases autoimmune blistering disease risk, while vaccination appears protective, researchers report in a study analyzing 112 million patient records

Conexiant

March 03, 2025

More States Fast Track Foreign-Trained Physicians

Since 2023, nine states have waived U.S. residency requirements for some foreign-trained physicians, with more states considering similar changes.

KFF Health News

February 26, 2025

New Medical Malpractice Rules Issued by American Law Institute

The American Law Institute's first restatement of medical malpractice law shifts focus from customary practice to evidence-based medicine.

Conexiant

February 24, 2025

Do Black Female Doctors Die Earlier?

New JAMA Internal Medicine study finds Black female physicians face higher mortality rates than White women in general population.

Conexiant

February 19, 2025

Recurrent Hyperpigmented Patches After GLP-1 Therapy: What's Your Diagnosis?

A 62-year-old female developed fixed drug eruption following semaglutide administration, highlighting the importance of recognizing unusual dermatologic reactions during treatment with glucagon-like peptide-1 receptor agonists.

Conexiant